Introduction The University of Illinois, abbreviated as UI or U of I, was founded in 1867 and is one of the most influential public university systems in the United States. It is known as the "Public Ivy League" and is renowned worldwide. Its three campuses are located in the university town of Urbana Champagne, Illinois, the largest city of Chicago, and the state capital Springfield. |
Top 5 Drug Type | Count |
---|---|
Small molecule drug | 26 |
Synthetic peptide | 4 |
Chemical drugs | 4 |
Monoclonal antibody | 2 |
Biological products | 1 |
Target- |
Mechanism Vitamin C supplements |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc. China |
First Approval Date01 Jan 1981 |
Mechanism DNMT1 inhibitors [+6] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication |
Drug Highest PhaseApproved |
First Approval Ctry. / Loc.- |
First Approval Date- |
Target |
Mechanism ETB antagonists [+1] |
Active Org. |
Originator Org. |
Active Indication |
Inactive Indication- |
Drug Highest PhasePhase 3 |
First Approval Ctry. / Loc.- |
First Approval Date- |
Start Date01 Oct 2025 |
Sponsor / Collaborator |
Start Date01 Aug 2025 |
Sponsor / Collaborator |
Start Date01 Aug 2025 |
Sponsor / Collaborator |
Drug(Targets) | Indications | Global Highest Phase |
---|---|---|
VRP-1620 ( ETB ) | Breast Cancer More | Phase 3 |
RiMO-301 ( IDO1 ) | Head and neck cancer metastatic More | Phase 2 Clinical |
Dornase alfa biosimilar(University of Illinois) ( DNase I ) | Graft vs Host Disease More | Phase 2 |
Elraglusib ( GSK-3β ) | Colorectal Cancer More | Phase 2 |
TTC-352 ( ERα ) | Breast Cancer More | Phase 1 |